The approval allows Editas to move EDIT-401 from laboratory work into people for the first time. The therapy is designed to treat hyperlipidemia — persistently elevated blood fats that raise the risk of heart disease and remain, for a meaningful share of patients, difficult to manage adequately with existing drugs.
The RSS summary does not specify which regulatory body granted clearance, what dose or delivery method is planned, how many participants will be enrolled, or what the primary safety endpoints are. Those details matter considerably at this stage: first-in-human trials exist to establish that a treatment does not cause unacceptable harm, not to demonstrate that it works. A green light to begin is not evidence of efficacy, and results from an early-phase trial — whenever they arrive — will need to be read with that limit in mind.
What the announcement does establish is that gene-editing technology, long discussed as a future option for cardiovascular disease, has now cleared the threshold required to be tested directly in patients with the condition. Whether EDIT-401 will prove safe enough to advance further is precisely the question the trial is designed to answer.
Marcus Azzopardi 
Harvey Jr.